Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

2 high-quality ASX shares I’d buy in April 2022

I think that in periods of uncertainty and volatility, high-quality ASX shares could be the way to go, like Volpara Health (ASX:VHT).

I think that in periods of uncertainty and volatility, high-quality ASX shares could be the way to go.

Quality could mean different things to different people.

It could mean great management. Quality could mean the resilience of earnings. It could mean a strong balance sheet. There are other things it could refer to like growth, return on equity (ROE) and so on.

Here are two quality ASX shares to consider:

Betashares Global Quality Leaders ETF (ASX: QLTY)

This is an exchange-traded fund (ETF) that is based on a portfolio of quality businesses which rank well on a number of factors: return on equity, debt-to-capital, cash flow generation ability and earnings stability.

When you combine those four factors together, what remains is a quality group of businesses which are very profitable and produce good cash flow.

It’s not just a US-based portfolio, ‘only’ 60% of country allocation has (currently) gone to the US. Plenty of other countries get good weightings such as Japan, Switzerland, the Netherlands, Hong Kong and France.

There are 150 names in this portfolio, which means it’s nicely diversified in my opinion. Some positions include: Nvidia, AIA, Applied Materials, Advanced Micro Devices, ASML, Meta Platforms (Facebook), Intel, Visa, Accenture and Alphabet.

With all of these positives, the final one to note about this quality ASX share is that it only comes with an annual fee of just 0.35%.

Volpara Health Technologies Ltd (ASX: VHT)

I think that Volpara Health Technologies is one of the most promising quality ASX shares. The Volpara share price has fallen over 20% since the start of the year, but I think this could be a promising time to consider the business.

It provides breast screening software, as well as risk analysis for those women. Volpara also has practice management software.

Volpara is steadily winning over more clients in the US. It now has a market share of over 35% of US women being screened. That’s a very strong position to be in for the business. It has a very high retention rate, so once users are ‘in’ the system, they’re sticking around. I wouldn’t be surprised to see the market share continue to rise in the US.

Annual recurring revenue (ARR) also keeps rising, giving investors good visibility about the next 12 months of base revenue. At 31 December 2021, Volpara’s ARR was was US$21.5 million, up almost US$1.1 million over the September 2021 quarter. Volpara has a very high gross profit margin, so most of the new revenue turns into more gross profit.

Volpara is going to try to grow its average revenue per user (ARPU) in a number of ways, by selling a platform, not just a product. Most new sales are now for two or three products, representing significantly increased ARPU.

Organic ARPU growth can happen thanks to fresh deals signing up with multiple products. It can also upsell to existing users. The company said it sees a 200% to 300% increase in recurring revenue for those that upgraded.

I think that the company has a very promising future with non-US growth over the long-term. Europe and Canada could be two fruitful areas to pursue.

Lung cancer screening is another area that the quality ASX share has a presence in, which could become a much bigger opportunity over time as the issue gains patient awareness.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content